Advertisement

Clinical Drug Investigation

, Volume 12, Issue 1, pp 1–7 | Cite as

NeuRecover-SA™ in the Treatment of Cocaine Withdrawal and Craving

A Pilot Study
  • Julie A. Cold
Clinical Use

Summary

The efficacy of NeuRecover-SA™ (formerly called Tropamine+™, and TropaGen™) in the treatment of cocaine withdrawal and craving was evaluated at a state psychiatric hospital. This double-blind, placebo-controlled study was conducted in hospitalised patients with a DSM-III-R diagnosis of cocaine dependence. Eight patients received NeuRecover-SA™ and 4 patients received placebo. No significant difference in patient demographics was found. The mean number of abstinent symptoms (± SEM) declined over the first 4 days of treatment, 10.63 ± 1.32 on day 1 vs 4 ± 1.65 on day 4 in the NeuRecover-SA™ group compared with 7.25 ± 2.93 on day 1 vs 4.25 ± 3.61 on day 4 in the placebo group. Cocaine craving in the NeuRecover-SA™ group on day 1 was 7.88 ± 1.22 vs 2.71 ± 1.22 on day 4 and 5 ± 2.89 on day 1 vs 2 ± 1.68 on day 4 in the placebo group. A Mann-Whitney U test showed no statistically significant differences in abstinent symptomatology between or within treatment groups, or treatment effect in the placebo group. However, a significant decrease (p < 0.05) in cocaine craving occurred in the NeuRecover-SA™ group.

In conclusion, these preliminary results suggest that NeuRecover-SA™ reduces cocaine craving, and larger, longer term studies are warranted.

Keywords

Cocaine Adis International Limited Drug Invest Trazodone Cocaine Dependence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hall WC, Talbert RL, Ereshefsky L. Cocaine abuse and its treatment. Pharmacotherapy 1990; 10: 47–65PubMedGoogle Scholar
  2. 2.
    Khantzian EJ, Bean-Bayog M, Blumenthal S, et al. Substance abuse disorders: a psychiatric priority. Am J Psychiatry 1991; 148: 1291–300Google Scholar
  3. 3.
    Dixon L, Haas G, Weiden PJ, et al. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991; 148: 224–30PubMedGoogle Scholar
  4. 4.
    Trachtenberg MC, Blum K. Improvement of cocaine-induced neuromodulator deficits by the neuronutrient Tropamine. J Psychoact Drugs 1988; 20(3): 315–31CrossRefGoogle Scholar
  5. 5.
    Grace AA. The tonic/phasic model of dopamine system regulation: its relevance for understanding how stimulant abuse can alter basal ganglia function. Drug Alcohol Depend 1995; 37: 111–29PubMedCrossRefGoogle Scholar
  6. 6.
    McKay JR, Rutherford MJ, Alterman AI, et al. An examination of the cocaine relapse process. Drug Alcohol Depend 1995; 38: 35–43PubMedCrossRefGoogle Scholar
  7. 7.
    Lacombe S, Stanislav SW, Marken PA. Pharmacologic treatment of cocaine abuse. DICP Ann Pharmacother 1991; 25: 818–23Google Scholar
  8. 8.
    Grabowski J, Rhoades H, Elk R, et al. Fluoxetine is ineffective for treatment of cocaine dependence or concurrent opiate and cocaine dependence: two placebo-controlled, double-blind trials. J Clin Psychopharmacol 1995; 15(3): 163–74PubMedCrossRefGoogle Scholar
  9. 9.
    Nunes EV, McGrath PJ, Quitkin FM, et al. Imipramine treatment of cocaine abuse: possible boundaries of efficacy. Drug Alcohol Depend 1995; 39: 185–95PubMedCrossRefGoogle Scholar
  10. 10.
    Kranzler HR, Vauer LO, Hersh D, et al. Carbamazepine treatment of cocaine dependence: a placebo-controlled trial. Drug Alcohol Depend 1995; 38: 203–11PubMedCrossRefGoogle Scholar
  11. 11.
    Montoya ID, Levin FR, Fudala PJ, et al. Double-blind comparison of carbamazepine and placebo for treatment of cocaine dependence. Drug Alcohol Depend 1995; 38: 213–9PubMedCrossRefGoogle Scholar
  12. 12.
    Cornish JW, Maany I, Fudala PJ, et al. Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend 1995; 38: 221–7PubMedCrossRefGoogle Scholar
  13. 13.
    Blum K, Allison D, Trachtenberg MC, et al. Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30-day inpatient treatment program by the neuronutrient Tropamine. Curr Ther Res 1988; 43(6): 1204–14Google Scholar
  14. 14.
    McGovern MP, Morrison DH. The Chemical Use, Abuse, and Dependence Scale (CUAD). J Subst Abuse Treat 1992; 9: 27–38PubMedCrossRefGoogle Scholar
  15. 15.
    Abstinence Symptom Evaluation Scale for Cocaine Withdrawal. Modified form of the Abstinence Symptom Evaluation (ASE) Scale created by David Knott, MD, at the Tennessee Government Hospital in Memphis, TennesseeGoogle Scholar
  16. 16.
    Halikas JA, Kuhn KL, Crosby R, et al. The measurement of craving in cocaine patients using the Minnesota Cocaine Craving Scale. Compr Psychiatry 1991; 32(1): 22–7PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Julie A. Cold
    • 1
    • 2
  1. 1.Mercer University Southern School of PharmacyAtlantaUSA
  2. 2.Georgia Regional Hospital at AtlantaDecaturUSA

Personalised recommendations